Loading...
Back to narrative

AnalystConsensusTarget updated the narrative for INGN

Update shared on 03 Nov 2025

n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-37.0%
7D
-15.2%

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.

What's in the News

  • Inogen, Inc. provided earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million. This projection represents about 4% growth compared to the third quarter of 2024 (Company Guidance).
  • Full-year 2025 expected revenue is in the range of $354 million to $357 million. This would be approximately 6% higher than the company's 2024 revenue (Company Guidance).

Valuation Changes

  • Fair Value remains essentially unchanged at $13.00 per share.
  • Discount Rate has risen slightly from 7.56% to 7.63%.
  • Revenue Growth is unchanged at 6.93%.
  • Net Profit Margin increased from 12.32% to 12.88%.
  • Future P/E has fallen slightly from 10.32x to 9.88x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.